Wockhardt Files EMA Application for Novel Antibiotic WCK 5222
ECONOMY & POLICY

Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Related Stories

Gold Stories

Next Story
Infrastructure Urban

Vedanta Metal Bazaar Expands to Global Markets

Vedanta Aluminium has expanded its digital e-commerce platform, Vedanta Metal Bazaar, to international markets, enabling overseas customers to order and purchase aluminium products online.The platform will now be available to buyers across Asia, Europe, Africa and the Americas, providing a digital gateway for export transactions with 24x7 access.In FY26, Vedanta Metal Bazaar processed transactions worth nearly $4.1 billion, or over Rs 380 billion, and fulfilled more than 23,000 orders. The platform is also used regularly by more than 550 MSMEs in India alongside large OEM customers.The export ..

Next Story
Infrastructure Urban

Ramky Infrastructure Q1 FY27 Revenue Rises 24.3%

Ramky Infrastructure Limited reported a 24.3% year-on-year increase in consolidated revenue from operations to Rs 471.2 crore for Q1 FY27, compared with Rs 3.79 billion in the corresponding quarter of FY26.Standalone revenue from operations rose 27.5% YoY to Rs 4.51 billion from Rs 3.54 billion, while total standalone income increased 35% to Rs 5.32 billion.Consolidated profit before tax stood at Rs 540.9 million during the quarter. The company highlighted a sharp sequential improvement compared with a pre-exceptional loss of Rs 190.1 million in Q4 FY26.Two of the three projects awarded during..

Next Story
Technology

LTTS Launches AgenticIQ AI Platform for Engineering

L&T Technology Services (LTTS) has launched AgenticIQ, an end-to-end agentic AI platform designed for engineering and manufacturing organisations.The platform is aimed at helping enterprises move beyond isolated AI pilots by enabling autonomous, multi-agent workflows across engineering, product development, manufacturing, industrial operations and customer experience.AgenticIQ is built on LTTS’ Engineering Intelligence portfolio and converts existing engineering capabilities into specialised, reusable AI agents. Its planning-first architecture is embedded into engineering and production ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement